Results 41 to 50 of about 30,354 (250)

Premature Coronary Artery Disease due to Homozygous Familial Hypercholesterolemia in a 12-Year-Old Girl

Balkan Medical Journal, 2018
Background: Homozygous familial hypercholesterolemia is a rare inherited metabolic disease caused by low-density lipoprotein receptor abnormality.
Filiz Ekici, Salih Özçobanoğlu, Fırat Kardelen   +2 more
doaj   +1 more source

The panorama of familial hypercholesterolemia in Latin America: a systematic review[S]

Journal of Lipid Research, 2016
The burden caused by familial hypercholesterolemia (FH) varies among countries and ethnic groups. The prevalence and characteristics of FH in Latin American (LA) countries is largely unknown. We present a systematic review (following the PRISMA statement)
Roopa Mehta, Rafael Zubirán, Alexandro J. Martagón, Alejandra Vazquez-Cárdenas, Yayoi Segura-Kato, María Teresa Tusié-Luna, Carlos A. Aguilar-Salinas   +6 more
doaj   +1 more source

Recent Advances on Familial Hypercholesterolemia in Children and Adolescents

Biomedicines, 2022
Familial hypercholesterolemia is a common autosomal hereditary disorder characterized by elevated concentrations of low-density lipoprotein cholesterol and the development of premature atherosclerosis and cardiovascular disease.
Francesca Mainieri, Veronica Maria Tagi, Francesco Chiarelli   +2 more
doaj   +1 more source

Familial hypercholesterolemia: a systematic review of guidelines on genetic testing and patient management [PDF]

, 2017
BACKGROUND: Familial hypercholesterolemia (FH) is an autosomal-dominant hereditary disorder of lipid metabolism that causes lifelong exposure to increased LDL levels resulting in premature coronary heart disease and, if untreated, death.
Baccolini, Valentina, D'Andrea, Elvira, De Vito, Corrado, Massimi, Azzurra, Migliara, Giuseppe, Rosso, Annalisa, Villari, Paolo   +6 more
core   +2 more sources

ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia—Brief Report

Arteriosclerosis, Thrombosis and Vascular Biology, 2021
Supplemental Digital Content is available in the text. Objective: The mechanism by which evinacumab, a fully human monoclonal antibody directed against ANGPTL3 (angiopoietin-like 3 protein) lowers plasma LDL (low-density lipoprotein) cholesterol levels ...
L. Reeskamp, J. Millar, Liya Wu, H. Jansen, D. van Harskamp, H. Schierbeek, D. Gipe, D. Rader, G. Dallinga-Thie, G. Hovingh, M. Cuchel   +10 more
semanticscholar   +1 more source

Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia [PDF]

, 2017
Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reduction ...
Bray, Sarah, Bridges, Ian, Cheng, Lung-I, Dent, Ricardo, Deshpande, Sohan, Forbes, Carol A., Gandra, Shravanthi R., Kleijnen, Jos, Ross, Janine, Sattar, Naveed, Stroes, Erik S.G., Toth, Peter P., Worth, Gavin M., Worthy, Gillian   +13 more
core   +1 more source

Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study

Arteriosclerosis, Thrombosis and Vascular Biology, 2022
Background: Despite progress in treating homozygous familial hypercholesterolemia, most patients do not achieve low-density lipoprotein cholesterol (LDL-C) targets.
É. Bruckert, S. Caprio, A. Wiegman, M. Charng, Cézar A. Zárate-Morales, M. Baccara-Dinet, G. Manvelian, Anne Ourliac, M. Scemama, Stephen R. Daniels   +9 more
semanticscholar   +1 more source

Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies. [PDF]

Arterioscler Thromb Vasc Biol
BACKGROUND: Pediatric patients with homozygous familial hypercholesterolemia (HoFH) have an increased risk of atherosclerotic cardiovascular disease and difficulty meeting low-density lipoprotein cholesterol (LDL-C) goals.
Raal FJ, Hegele RA, Ruzza A, López JAG, Bhatia AK, Wu J, Wang H, Gaudet D, Wiegman A, Wang J, Santos RD.   +10 more
europepmc   +2 more sources

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society [PDF]

, 2014
AIMS: Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening condition characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular ...
Averna, M, AVERNA, Maurizio, Boileau, C, Boileau, C, Boren, J, Boren, J, Bruckert, E, Bruckert, E, Catapano, A, Catapano, A, Chapman, M, Chapman, M, Chapman, M, Cuchel, M, Cuchel, M, Defesche, J, Defesche, J, Descamps, O, Descamps, O, Ginsberg, H, Ginsberg, H, Ginsberg, H, Hegele, R, Hegele, R, Hovingh, G, Hovingh, G, Humphries, S, Humphries, S, Kovanen, P, Kovanen, P, Kuivenhoven, J, Kuivenhoven, J, Masana, L, Masana, L, Nordestgaard, B, Nordestgaard, B, Pajukanta, P, Pajukanta, P, Parhofer, K, Parhofer, K, Raal, F, Raal, F, Ray, K, Ray, K, Santos, R, Santos, R, Stalenhoef, A, Stalenhoef, A, Steinhagen Thiessen, E, Steinhagen Thiessen, E, Stroes, E, Stroes, E, Taskinen, M, Taskinen, M, Tybjaerg Hansen, A, Tybjaerg Hansen, A, Watts, G, Watts, G, Wiegman, A, Wiegman, A, Wiklund, O, Wiklund, O.   +61 more
core   +1 more source

Is Liver Transplant Curative in Homozygous Familial Hypercholesterolemia? A Review of Nine Global Cases

Advances in Therapy, 2022
Introduction Homozygous familial hypercholesterolemia (HoFH) is a rare, life-threatening, inherited condition characterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C).
Mohammed Al Dubayee, M. Kayıkçıoğlu, Jeanine Roeters van Lennep, N. Hergli, P. Mata   +4 more
semanticscholar   +1 more source